Abstract:<p>Chemotherapeutic strategy has been widely used for treating malignance by targeting irregular expressed or mutant proteins with small molecular inhibitors (SMIs) or monoclonal antibodies (mAbs). However, most intracellular proteins lack of active sites or antigens where SMIs or mAbs bind with, and are called as non-druggable targets for a long time. From the first year of this century, PROteolysis-TArgeting Chimeras (PROTACs) has emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins. The first generation of peptide-based PROTACs adopts β-TrCP and VHL as E3 ligases, but the cellular permeability and chemical stability issues restrict their clinical application. The second generation of small molecule-based PROTACs adopts MDM2, VHL, IAPs and Cereblon as E3 ligases have been tensely studied. To date, the targets of PROTACs including those overexpressed oncogenic proteins such as ER, AR and BRDs, disease-relevant fusion proteins such as NPM/EML4-ALK and BCL-ABL, cancer-driven mutant proteins such as EGFR, kinases such as CDKs and RTKs. The major disadvantage of PROTACs is the noncancer specificity and relative higher toxicity, due to its catalytic role. To overcome this, we and other have recently developed several similar light-controllable PROTACs, termed as the third generation controllable PROTACs. The degradation of targets by those PROTACs can be triggered by UVA or visible light, providing a tool box for further PROTACs design. Here in this review, we introduce the historical milestones and prospective for further PROTACs development in clinical use.</p>

Cancer Selective Target Degradation By Folate-Caged Protacs

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Folate-PEG-PROTAC Micelles for Enhancing Tumor-Specific Targeting Proteolysis In Vivo.

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

PROTACs: A novel strategy for cancer therapy

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

PROTACs in gastrointestinal cancers

Clinical considerations for the design of PROTACs in cancer

Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer

Development of PROTAC Degrader Drugs for Cancer

Recent Advances in Optically Controlled PROTAC